Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Verrica Pharmaceuticals Q3 2026 Results: Net Loss of $12.4M, Loss Widens

Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue6.914.3
Net income-12.4-0.3
EPS (diluted, $ a share)$-0.58$-0.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-51.8%
Operating margin-176.0%
Source

10-Q filed with the SEC, NASDAQ: VRCA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Verrica Pharmaceuticals Inc.: key numbers

Share price
$3.20Close, Nov 16
Market cap
$55M
Shares outstanding
17.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Verrica Pharmaceuticals Inc.

All →
4:28 PM ET 8-K
Financial Results

Verrica Pharmaceuticals Financial Results

Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.

Term
Q3 2026

“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”

Jayson Rieger, PhD, MBA, President and Chief Executive Officer

“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”

Jayson Rieger, PhD, MBA, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.